XVA143, an α β I-like allosteric antagonist, inhibits LFA-1 dependent firm adhesion, while at the same time it enhances adhesion in shear flow and rolling both in vitro and in vivo. XVA143 is an antagonist of both mouse and human CR3, inhibits the ability of P. gingivalis to persist in the mouse host and cause periodontal bone loss.
Flurbiprofen sodium is an anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting carbonic anhydrase.